C4 Therapeutics

Valuation Analysis

About the Company

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGA

C4 Therapeutics Stock at a Glance

C4 Therapeutics (CCCC) is currently trading at $4.14 with a market capitalization of $457.7M. The 52-week range spans from $1.44 to $5.17; the current price is 19.9% below the yearly high. Year-over-year revenue growth stands at -15.0%.

💰 Dividend

C4 Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

6 analysts rate C4 Therapeutics (CCCC) on consensus: Strong Buy. The average price target is $13.33, implying +222.06% from the current price. Analyst price targets range from $7.00 to $30.00.

C4 Therapeutics: The Investment Case in Detail

C4 Therapeutics (CCCC) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

With a gross margin near 78.34%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 222.06% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Revenue is contracting at -15% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 2.91, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves.

What to Watch Next

• The analyst consensus price target implies 222.06% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to above-average price swings, elevated short interest (20.25%).

Trading Data

Related Stocks in the Same Sector

Where can I buy C4 Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.